Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Dr. Falk Pharma GmbH
ClinicalTrials.gov Identifier:
NCT01510860
First received: January 12, 2012
Last updated: January 17, 2012
Last verified: January 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2010
  Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)